In the BioHarmony Drug Report Database
Alemtuzumab
Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
Trade Name
|
Lemtrada |
|---|---|
Common Name
|
alemtuzumab |
ChEMBL ID
|
CHEMBL1201587 |
Indication
|
b-cell chronic lymphocytic leukemia, multiple sclerosis |
Drug Class
|
Monoclonal antibodies: humanized, tumors as target |
Image (chem structure or protein)
